14071
document
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine . A number of quinolone antibacterial agents , particularly enoxacin , pefloxacin , pipemidic acid and ciprofloxacin , are known to decrease the clearance of methylxanthines . The effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine were therefore compared in a 3-way crossover study in 12 healthy young volunteers . Each volunteer received 183mg once-daily doses of caffeine in conjunction with twice-daily placebo , temafloxacin 600mg and ciprofloxacin 750mg in 3 separate phases according to a randomised sequence . A doubling of the area under the plasma concentration-time curve ( 77.8 vs 31.8 mg/L.h ) and terminal-phase half-life ( 9.7 vs 4.5h ) of caffeine were observed in the presence of ciprofloxacin . The magnitude of the reduction in the intrinsic clearance of caffeine produced by ciprofloxacin was greater than that described in the literature for ciprofloxacin and theophylline . This may partly be explained by intertrial differences in dosage and study design . Coadministration of temafloxacin did not have any effect on the pharmacokinetics of caffeine , confirming results of other studies suggesting that this agent does not affect methylxanthine clearance . Accordingly , it appears that restriction of caffeine intake during temafloxacin therapy is not necessary .
14072
Intervention_Pharmacological
temafloxacin
14073
Intervention_Pharmacological
ciprofloxacin
14074
Intervention_Pharmacological
ciprofloxacin
14075
Intervention_Pharmacological
temafloxacin
14076
Intervention_Pharmacological
ciprofloxacin
14077
Intervention_Pharmacological
183mg once-daily doses of caffeine
14078
Intervention_Control
placebo
14079
Intervention_Pharmacological
temafloxacin 600mg
14080
Intervention_Pharmacological
ciprofloxacin 750mg
14081
Intervention_Pharmacological
caffeine
14082
Intervention_Pharmacological
ciprofloxacin
14083
Intervention_Pharmacological
ciprofloxacin
14084
Intervention_Pharmacological
theophylline
14085
Intervention_Pharmacological
temafloxacin
14086
Intervention_Pharmacological
temafloxacin
14087
Outcome_Other
area under the plasma concentration-time curve
14088
Outcome_Other
terminal-phase half-life
14089
Outcome_Other
magnitude of the reduction in the intrinsic clearance of caffeine
14090
Outcome_Other
pharmacokinetics of caffeine
14091
Outcome_Other
methylxanthine clearance
14092
Participant_Sample-size
12
14093
Participant_Condition
healthy
14094
Participant_Age
young